CN106366076A - Posaconazole synthesis method - Google Patents

Posaconazole synthesis method Download PDF

Info

Publication number
CN106366076A
CN106366076A CN201610755734.XA CN201610755734A CN106366076A CN 106366076 A CN106366076 A CN 106366076A CN 201610755734 A CN201610755734 A CN 201610755734A CN 106366076 A CN106366076 A CN 106366076A
Authority
CN
China
Prior art keywords
posaconazole
group
acid
reactor
reaction
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN201610755734.XA
Other languages
Chinese (zh)
Other versions
CN106366076B (en
Inventor
殷殿书
魏赛丽
孙曼
印杰
刘玉扑
胡硕
武玉杰
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hebei Guangxiang Pharmaceutical Technology Co Ltd
Original Assignee
Hebei Guolong Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hebei Guolong Pharmaceutical Co Ltd filed Critical Hebei Guolong Pharmaceutical Co Ltd
Priority to CN201610755734.XA priority Critical patent/CN106366076B/en
Publication of CN106366076A publication Critical patent/CN106366076A/en
Application granted granted Critical
Publication of CN106366076B publication Critical patent/CN106366076B/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The invention provides a posaconazole synthesis method which includes the steps: S1, taking a compound displayed by a following formula II as a raw material, taking hydrogen as a hydrogen source, stirring the compound displayed by the formula II, catalysts and acidic reagents in reaction solvents under the hydrogenation debenzylation reaction condition, and performing contact reaction to obtain mixed solution; S2, reducing the temperature of the mixed solution to range from 0 DEG C to 5 DEG C, dropping sodium hydroxide solution into the mixed solution until a pH (potential of hydrogen) value of the mixed solution is 10-12, stirring, filtering to obtain filter cakes, washing the filter cakes, and drying the washed filter cakes to obtain posaconazole as shown in the following formula I.

Description

一种泊沙康唑的合成方法A kind of synthetic method of posaconazole

技术领域technical field

本发明涉及药物合成领域,一种泊沙康唑的合成方法。The invention relates to the field of drug synthesis, and relates to a method for synthesizing posaconazole.

背景技术Background technique

泊沙康唑(中文化学名:4-[4-[4-[4-[[(3R,5R)-5-(2,4-二氟苯基)-5-(1,2,4-三唑-1-基甲基)氧杂戊环-3-基]甲氧基]苯基]哌嗪-1-基]苯基]-2-[(2S,3S)-2-羟基戊-3-基]-1,2,4-三唑-3-酮),具有下式I所示结构。Posaconazole (Chinese chemical name: 4-[4-[4-[4-[[(3R,5R)-5-(2,4-difluorophenyl)-5-(1,2,4- Triazol-1-ylmethyl)oxolan-3-yl]methoxy]phenyl]piperazin-1-yl]phenyl]-2-[(2S,3S)-2-hydroxypentyl- 3-yl]-1,2,4-triazol-3-one), has the structure shown in the following formula I.

泊沙康唑是由德国先灵葆雅公司研制,商品名“Noxafil”,于2005年10月20日在欧盟和美国FDA获得批准上市的抗真菌药物。泊沙康唑口服混悬液于2006年9月再次获美国FDA批准用于骨髓移植后免疫力减弱和癌症化疗引起白细胞减少的患者,以防止曲霉菌和念珠菌引起的感染。由于其具有高效低毒的特点,且临床应用范围广,疗效较好,尤其是对多烯类化合物和其他三唑类耐药或侵袭性真菌感染有效,为临床侵袭性真菌感染的治疗提供了选择空间。Posaconazole is an antifungal drug developed by Schering-Plough in Germany under the trade name "Noxafil", which was approved for marketing in the European Union and the US FDA on October 20, 2005. In September 2006, posaconazole oral suspension was once again approved by the US FDA for patients with weakened immunity after bone marrow transplantation and leukopenia caused by cancer chemotherapy to prevent infections caused by Aspergillus and Candida. Because of its high efficiency and low toxicity, wide range of clinical applications, and good curative effect, it is especially effective for polyenes and other triazole-resistant or invasive fungal infections, and provides a great opportunity for the treatment of clinical invasive fungal infections. Choose a space.

现有技术中关于泊沙康唑的合成方法已有大量研究,一般最终均由如下式II所示化合物氢化脱苄基得到泊沙康唑。There have been a lot of researches on the synthesis method of posaconazole in the prior art, and generally, posaconazole is finally obtained by hydrogenation debenzylation of the compound shown in the following formula II.

US5625064和CN101824009A中记载:将式II所示化合物冷却至50℃,加入350ml甲酸,继续冷却至20℃,加入另外350ml甲醇,取85gPd/C加入350ml甲酸搅拌成浆状加入反应瓶中,在20℃下搅拌过夜,加热至40℃反应24h,抽滤,滤饼用350ml甲酸、700ml甲醇淋洗。减压蒸干溶剂,向残余物中加入3500ml甲醇和700ml氨水,加热至回流1-2h,然后冷却析出大量固体,抽滤,滤饼用1400ml甲醇和水(1:1)洗涤,40℃下鼓风烦躁得到300.5g终产物。It is recorded in US5625064 and CN101824009A: cool the compound shown in formula II to 50°C, add 350ml of formic acid, continue to cool to 20°C, add another 350ml of methanol, take 85gPd/C and add 350ml of formic acid to stir into a slurry and add it to the reaction flask. Stir overnight at °C, heat to 40°C for 24 hours, filter with suction, and wash the filter cake with 350ml formic acid and 700ml methanol. Evaporate the solvent under reduced pressure, add 3500ml of methanol and 700ml of ammonia water to the residue, heat to reflux for 1-2h, then cool to precipitate a large amount of solid, filter with suction, wash the filter cake with 1400ml of methanol and water (1:1), at 40°C Blowing and irritating gave 300.5 g of the final product.

Anil K.Saksena(Tetrahedron Letters 45(2004)8249–8251)指出:将4.03g式II所述化合物溶于70ml甲酸中,再加入5%Pd/C 8g,反应混合物在20℃下搅拌15h,然后加热至35-40℃,再搅拌24h。然后将反应液降温至20℃,过滤,并用约40ml甲酸洗涤滤饼,再用35ml甲醇洗涤滤饼两次,滤液旋蒸至干得剩余物,柱层析,得泊沙康唑3g,收率为84%。Anil K. Saksena (Tetrahedron Letters 45 (2004) 8249-8251) pointed out: 4.03g of the compound described in formula II was dissolved in 70ml of formic acid, then 5% Pd/C 8g was added, the reaction mixture was stirred at 20°C for 15h, and then Heated to 35-40°C and stirred for another 24h. Then the reaction solution was cooled to 20°C, filtered, and the filter cake was washed with about 40ml of formic acid and twice with 35ml of methanol. The rate is 84%.

上述工艺方法中泊沙康唑的合成路线如下The synthetic route of posaconazole in the above-mentioned processing method is as follows

在以上两种方式中,甲酸即为反应溶剂,也是氢源。先在20°下反应,再升高温度至35-40℃反应,总反应时间均超过40h,且后处理需柱层析纯化样品,溶剂量太大,不适应于大生产。In the above two methods, formic acid is the reaction solvent and hydrogen source. First react at 20°C, and then increase the temperature to 35-40°C for reaction. The total reaction time is more than 40h, and the post-processing requires column chromatography to purify the sample. The amount of solvent is too large, which is not suitable for large-scale production.

在CN102863431A中记载:250ml三口瓶中加入式II所示化合物(8.12g)和氢溴酸70ml,搅拌至固体溶解,加热至50℃反应2-3h,液相监测反应完毕。反应液用水(100ml)稀释,NaOH水溶液(100ml,25%)调节至pH约为9,二氯甲烷(100ml)萃取,有机相10%NaOH水溶液(100ml)洗涤,水(100ml)洗涤,饱和NaCl水溶液(100ml)洗涤,无水NaSO4干燥,浓缩,真空干燥,得到土黄色粗产物,纯度为93.9%。该实验方法中,氢溴酸即为反应溶剂也为氢源,其具有强烈的棘刺味道且不易储存,易被氧化。且后处理繁琐,收率低,不适合应用于大生产。It is recorded in CN102863431A: add the compound shown by formula II (8.12g) and hydrobromic acid 70ml into a 250ml three-necked flask, stir until the solid dissolves, heat to 50°C for 2-3h, and monitor the completion of the reaction by liquid phase. The reaction solution was diluted with water (100ml), adjusted to pH about 9 with aqueous NaOH solution (100ml, 25%), extracted with dichloromethane (100ml), washed with 10% aqueous NaOH solution (100ml) of the organic phase, washed with water (100ml), washed with saturated NaCl It was washed with aqueous solution (100ml), dried over anhydrous NaSO 4 , concentrated, and dried in vacuo to give an ocher crude product with a purity of 93.9%. In this experimental method, hydrobromic acid is both the reaction solvent and the hydrogen source, which has a strong thorny taste and is not easy to store and is easily oxidized. And post-processing is cumbersome and the yield is low, so it is not suitable for large-scale production.

此外,在WO2013042138A2和US2014343285A1中记载:在420ml甲醇中加入42g式II所示化合物,5mol/l盐酸和10%Pd-C,在4-5kg/cm2(0.4-0.5Mpa)氢气压力,反应温度50℃下反应5h,反应结束后,过滤除去催化剂,然后用4mol/L氢氧化钠溶液调节ph值为7左右,加入水并在25-35℃下搅拌2h,有大量固体析出,过滤,并用水洗涤滤饼,滤饼在异丙醇中重结晶得到泊沙康唑,收率为75%,纯度为99.85%。该工艺方法中泊沙康唑的合成路线如下:In addition, it is described in WO2013042138A2 and US2014343285A1: add 42g of the compound shown in formula II to 420ml of methanol, 5mol/l hydrochloric acid and 10%Pd-C, at 4-5kg/cm 2 (0.4-0.5Mpa) hydrogen pressure, reaction temperature React at 50°C for 5h. After the reaction is over, remove the catalyst by filtration, then use 4mol/L sodium hydroxide solution to adjust the pH value to about 7, add water and stir at 25-35°C for 2h, a large amount of solids precipitate, filter, and The filter cake was washed with water, and the filter cake was recrystallized in isopropanol to obtain posaconazole with a yield of 75% and a purity of 99.85%. The synthetic route of posaconazole in this processing method is as follows:

上述实验方案虽然在一定程度上缩短了反应时间,提高了标产物的纯度。然而为了能够实现泊沙康唑的大规模工业化生产,对于泊沙康唑的合成方法还有待于进一步优化和改进,以建立了一种反应时间更短、且泊沙康唑的纯度和收率均有所提高的泊沙康唑的合成方法。Although the above experimental scheme shortens the reaction time to a certain extent, it improves the purity of the target product. However, in order to realize the large-scale industrial production of posaconazole, the synthetic method of posaconazole needs to be further optimized and improved, so as to establish a method with shorter reaction time and the purity and yield of posaconazole Synthetic methods of posaconazole have been improved.

发明内容Contents of the invention

本发明的主要目的在于提供一种泊沙康唑的合成方法,以在提高泊沙康唑的收率和纯度的同时,提供一种适用于大规模工业化生产的泊沙康唑的合成方法。The main purpose of the present invention is to provide a synthetic method of posaconazole, so as to improve the yield and purity of posaconazole, and provide a synthetic method of posaconazole suitable for large-scale industrial production.

为此,在本发明中提供了一种泊沙康唑的合成方法,该合成方法包括下列步骤:For this reason, a kind of synthetic method of posaconazole is provided in the present invention, and this synthetic method comprises the following steps:

S1、以如下式II所示化合物为原料,以氢气为氢源,在氢化脱苄基反应条件下,将式II所示化合物与催化剂和酸性试剂在反应溶剂中搅拌接触反应,得到混合溶液;S1. Using the compound shown in the following formula II as a raw material, using hydrogen as a hydrogen source, under the conditions of the hydrogenation debenzylation reaction, stirring and contacting the compound shown in the formula II with a catalyst and an acidic reagent in a reaction solvent to obtain a mixed solution;

S2、将所述混合溶液降温至0-5℃,向所述混合溶液中滴加氢氧化钠溶液至混合溶液的pH值为10-12,搅拌过滤得滤饼,清洗后干燥得到如下式I所示的泊沙康唑。S2. Cool the mixed solution to 0-5°C, add sodium hydroxide solution dropwise to the mixed solution until the pH value of the mixed solution is 10-12, stir and filter to obtain a filter cake, wash and dry to obtain the following formula I posaconazole as indicated.

根据本发明的合成方法,添加催化剂的目的主要是促使氢化脱苄基反应发生,其中对于催化剂的使用并没有特殊要求,可以采用本领域能够促使氢化脱苄基反应发生的任意的催化剂。然而为了优化反应效果,提高泊沙康唑的收率,优选以含水量为50wt%的10%钯碳催化剂作为催化剂(其中10%钯碳催化剂为钯含量为催化剂干基重量的10wt%的催化剂),且所述10wt%钯碳催化剂的干重与式II所示化合物的重量比为(0.05-0.1):1,优选为(0.08-1):1,更优选为0.08:1。According to the synthesis method of the present invention, the purpose of adding the catalyst is mainly to promote the hydrodebenzylation reaction, wherein there is no special requirement for the use of the catalyst, and any catalyst that can promote the hydrodebenzylation reaction in the art can be used. Yet in order to optimize the reaction effect, improve the yield of posaconazole, be preferably 10% palladium carbon catalyst with water content as catalyzer (wherein 10% palladium carbon catalyst is the catalyst that palladium content is 10wt% of catalyzer dry basis weight) ), and the weight ratio of the dry weight of the 10wt% palladium-carbon catalyst to the compound shown in formula II is (0.05-0.1): 1, preferably (0.08-1): 1, more preferably 0.08: 1.

根据本发明的合成方法,添加酸性试剂的主要目的为了使式II溶解于反应溶剂中,其中对于酸性试剂的使用并没有特殊要求,可以是本领域常规的任意能够满足上述目的的有机酸或无机酸。然而为了优化反应效果,提高泊沙康唑的收率,优选所述酸性试剂与式II所示化合物的体积重量比为(0.5-1.5)L:1kg,更优选为1L:1kg。According to the synthesis method of the present invention, the main purpose of adding the acidic reagent is to dissolve the formula II in the reaction solvent, wherein there is no special requirement for the use of the acidic reagent, and it can be any conventional organic acid or inorganic acid that can meet the above-mentioned purpose in the art. acid. However, in order to optimize the reaction effect and increase the yield of posaconazole, the volume-to-weight ratio of the acidic reagent to the compound represented by formula II is preferably (0.5-1.5) L: 1 kg, more preferably 1 L: 1 kg.

优选地,所述酸性试剂为盐酸、硫酸,冰醋酸、甲酸和苯磺酸中的一种或多种,更优选所述酸性试剂为盐酸。在本发明中对于这些酸性试剂的浓度并没有特殊要求,可以根据实际需要调整。Preferably, the acidic reagent is one or more of hydrochloric acid, sulfuric acid, glacial acetic acid, formic acid and benzenesulfonic acid, more preferably the acidic reagent is hydrochloric acid. In the present invention, there is no special requirement for the concentration of these acidic reagents, which can be adjusted according to actual needs.

根据本发明的合成方法,重点在于以式II所示化合物为原料,以氢气为氢源在氢化脱苄基反应条件下进行搅拌反应,进而在加快反应效率的同时,提高泊沙康唑的收率,并简化后处理步骤。在本发明中对于步骤S1中氢化脱苄基反应条件并没有特殊要求,可以参照常规的合成方法中的相应条件,在本发明中优选所述氢化脱苄基反应条件包括:在常压、温度为50-55℃条件下,以350-450rpm的速度,搅拌反应2-3h。According to the synthesis method of the present invention, the focus is to use the compound shown in formula II as a raw material, and use hydrogen as a hydrogen source to carry out a stirring reaction under hydrogenation debenzylation reaction conditions, thereby increasing the yield of posaconazole while accelerating the reaction efficiency. rate and simplify the post-processing steps. In the present invention, there is no special requirement for the hydrogenation debenzylation reaction conditions in step S1, and the corresponding conditions in the conventional synthesis method can be referred to. In the present invention, the hydrogenation debenzylation reaction conditions preferably include: at normal pressure, temperature Under the condition of 50-55° C., the reaction was stirred for 2-3 hours at a speed of 350-450 rpm.

根据本发明的合成方法,为了满足步骤S1中搅拌反应的要求,优选情况下,促使步骤S1在内置有搅拌器的反应釜中进行。这种内置有搅拌器的反应釜可以采用常规市售的反应釜。然而为了优化搅拌效果,促使物料在搅拌的情况下进行传热、传质和反应,进而提高反应速率,在一种优选实施方式中,所述反应釜中搅拌器包括搅拌轴和沿所述搅拌轴的轴线方向均布的多组搅拌叶片组,各个搅拌叶片组中分别包括沿所述搅拌轴周向均布的1至3片搅拌叶片。优选地,相邻两组搅拌叶片组中搅拌叶片平行排布或者交错排布。优选的所述搅拌叶片沿所述反应釜径向的长度为所述搅拌釜半径的1/5-2/5倍,优选为1/3倍。According to the synthesis method of the present invention, in order to meet the requirements of the stirring reaction in step S1, preferably, step S1 is prompted to be carried out in a reaction kettle with a built-in stirrer. This built-in reactor with agitator can adopt a conventional commercially available reactor. However, in order to optimize the stirring effect, impel the material to carry out heat transfer, mass transfer and reaction under stirring, and then increase the reaction rate, in a preferred embodiment, the stirrer in the reactor includes a stirring shaft and a stirring shaft along the Multiple sets of stirring blade groups uniformly distributed along the axial direction of the shaft, each of which includes 1 to 3 stirring blades uniformly distributed along the circumference of the stirring shaft. Preferably, the stirring blades in two adjacent groups of stirring blades are arranged in parallel or alternately. Preferably, the length of the stirring blade along the radial direction of the reactor is 1/5-2/5 times, preferably 1/3 times, the radius of the stirring tank.

根据本发明的合成方法,为了进一步优化搅拌效果,促使反应加速,优选所述反应釜中还设有至少一组挡板组,所述一组挡板组中包括多个挡板、且各所述挡板的长度方向沿平行于所述搅拌器的轴线方向设置、宽度方向沿所述反应釜的径向方向设置。优选所述搅拌器沿所述反应釜的轴线设置,且所述一组挡板组中各所述挡板以所述搅拌器的轴线为垂直中分线呈圆周分布。优选的各所述挡板的高度为搅拌釜高度的1/2-2/3倍,宽度为所述搅拌釜半径的1/6-1/4倍,厚度为0.5-1cm。通过在搅拌釜中设置挡板组,促使被搅拌器搅动的液体与挡板发生冲击,促进式II所示化合物与氢气、催化剂、以及酸性试剂在搅拌的情况下进行传热、传质和反应,进而提高反应效率。According to the synthesis method of the present invention, in order to further optimize the stirring effect and accelerate the reaction, it is preferred that at least one set of baffles is also provided in the reactor, and the set of baffles includes a plurality of baffles, and each set The length direction of the baffle is set parallel to the axis of the agitator, and the width direction is set along the radial direction of the reactor. Preferably, the agitator is arranged along the axis of the reactor, and the baffles in the set of baffles are distributed in a circle with the axis of the agitator as the vertical midline. Preferably, the height of each baffle is 1/2-2/3 times the height of the stirred tank, the width is 1/6-1/4 times the radius of the stirred tank, and the thickness is 0.5-1 cm. By setting the baffle group in the stirred tank, the liquid agitated by the agitator is impelled to collide with the baffle, so as to promote the heat transfer, mass transfer and reaction of the compound shown in formula II with hydrogen, catalyst, and acidic reagent under the condition of stirring , thereby increasing the reaction efficiency.

在一种优选实施方式中,所述反应釜中设有一组挡板组,且该挡板组中各挡板沿其宽度延伸的方向,一侧固定在所述反应釜的内壁上,另一侧朝向所述搅拌器的位置延伸。In a preferred embodiment, a group of baffles is provided in the reaction kettle, and each baffle in the baffle group extends along its width, one side is fixed on the inner wall of the reaction kettle, and the other side is fixed on the inner wall of the reaction kettle. The side extends towards the position of the agitator.

在另一种优选实施方式中,所述反应釜中设置两组或三组挡板组,各所述挡板组以所述搅拌器的轴线为垂直中分线呈同心圆设置、且相邻两组挡板组中的挡板交错设置。In another preferred embodiment, two or three sets of baffles are set in the reactor, and each set of baffles is concentrically arranged with the axis of the agitator as the vertical midline and adjacent to each other. The baffles in the two groups of baffles are arranged in a staggered manner.

根据本发明的合成方法,在步骤S2中将所述混合溶液降温至0-5℃,在该步骤中对于所选择的降温方式并没有特殊要求,在本发明中优选直接在混合溶液中加入冰块以进行快速降温,这种快速降温能够减少副反应的发生。According to the synthesis method of the present invention, in step S2, the temperature of the mixed solution is lowered to 0-5°C. In this step, there is no special requirement for the selected cooling method. In the present invention, it is preferred to directly add ice to the mixed solution. block for rapid cooling, which can reduce the occurrence of side reactions.

在一种优选的实施方式中,根据本发明的合成方法包括以下步骤:S1、以如下式II所示化合物为原料,以氢气为氢源,将式II所示化合物、10%钯碳催化剂和酸性试剂按比例(具体比例参照前述说明,在此不再赘述)在反应釜中搅拌混合,在常压、50-55℃温度下,以350-450rpm的速度,搅拌反应2-3h(HPLC监测反应,控制反应终点),分离催化剂后得到混合溶液;其中所述反应釜为内置有搅拌器和任选的至少一组挡板组的反应釜(所述搅拌器和所述挡板组的结构如前所述在此不再赘述);S2、将所述混合溶液降温至0-5℃,向所述混合溶液中滴加碱性试剂至混合溶液的pH值为10-12,搅拌过滤得滤饼,清洗后干燥得到如下式I所示的泊沙康唑。In a preferred embodiment, the synthesis method according to the present invention comprises the following steps: S1, taking the compound shown in the following formula II as a raw material, using hydrogen as a hydrogen source, the compound shown in formula II, 10% palladium carbon catalyst and The acidic reagents are stirred and mixed in the reaction kettle in proportion (refer to the above description for the specific proportion, and will not be repeated here), and are stirred and reacted for 2-3 hours at a speed of 350-450 rpm under normal pressure and a temperature of 50-55 ° C (monitored by HPLC). reaction, control the reaction end point), and obtain the mixed solution after separating the catalyst; wherein the reaction kettle is a reaction kettle with a built-in agitator and at least one optional baffle group (the structure of the agitator and the baffle group As mentioned above, no more details here); S2, cooling the mixed solution to 0-5°C, adding an alkaline reagent dropwise to the mixed solution until the pH value of the mixed solution is 10-12, stirring and filtering to obtain The filter cake is washed and dried to obtain posaconazole shown in the following formula I.

根据本发明的合成方法,其中对于获取式II所示化合物的方法并没有特殊要求,其按照现有技术中的常规方法合成即可,例如:在100ml三口瓶中加入2-[(1S,2S)-1-乙基-2-苄氧基丙基]-2,4-二氢-4-[4-[4-(4-羟基苯基)-1-哌嗪基]苯基]-3H-1,2,4-三氮唑-3-酮(4.78g)和DMSO(40ml),搅拌溶解,加入浓度25wt%的NaOH水溶液(1.6ml),混合搅拌10分钟,加入(5R-CIS)-甲苯-4-磺酸5-(2,4-二氟苯基)-5-(1H-1,2,4-三氮唑-1-基)甲基四氢呋喃-3-基甲基酯(4.4g),混合物30℃反应约14h,液相监测至反应完毕,将反应液倒入剧烈搅拌的水(240ml)中,加毕,再剧烈搅拌10min,过滤,滤饼用水洗涤,将滤饼用异丙醇重结晶后得到固体,真空干燥得到灰白色粉末固体(式II)。According to the synthetic method of the present invention, wherein there is no special requirement for the method for obtaining the compound shown in formula II, it can be synthesized according to the conventional method in the prior art, for example: add 2-[(1S, 2S in a 100ml three-necked bottle )-1-ethyl-2-benzyloxypropyl]-2,4-dihydro-4-[4-[4-(4-hydroxyphenyl)-1-piperazinyl]phenyl]-3H -1,2,4-Triazol-3-one (4.78g) and DMSO (40ml), stirred and dissolved, added 25wt% NaOH aqueous solution (1.6ml), mixed and stirred for 10 minutes, added (5R-CIS) -Toluene-4-sulfonic acid 5-(2,4-difluorophenyl)-5-(1H-1,2,4-triazol-1-yl)methyltetrahydrofuran-3-ylmethyl ester ( 4.4g), the mixture was reacted at 30°C for about 14h, and the liquid phase was monitored until the reaction was completed. A solid was obtained after recrystallization from isopropanol, which was dried in vacuo to obtain an off-white powdery solid (Formula II).

同时,在本发明中还提供了一种由本发明所述的方法合成的泊沙康唑,优选所述泊沙康唑的纯度≥99%。At the same time, the present invention also provides posaconazole synthesized by the method of the present invention, preferably the purity of the posaconazole is ≥99%.

根据本发明所提供的泊沙康唑的合成方法以式II所示化合物为原料,以氢气为氢源,在搅拌条件下促使式II所示化合物发生氢化脱苄基反应。该方法不但降低了反应对于压力的要求,而且明显缩短了反应时间,只需2-3h即可;而且后处理简便,低温下调节ph值至10-12,离心,即可得到目标产物泊沙康唑,该方法适用于大规模的工业化生产。According to the synthesis method of posaconazole provided by the present invention, the compound represented by formula II is used as a raw material, hydrogen is used as a hydrogen source, and hydrogenation debenzylation reaction of the compound represented by formula II is promoted under stirring conditions. This method not only reduces the pressure requirements of the reaction, but also significantly shortens the reaction time, which only needs 2-3 hours; and the post-treatment is simple, and the pH value is adjusted to 10-12 at low temperature, and centrifuged to obtain the target product Posa Conazole, the method is suitable for large-scale industrial production.

附图说明Description of drawings

附图是用来提供对本发明的进一步理解,并且构成说明书的一部分,与下面的具体实施方式一起用于解释本发明,但并不构成对本发明的限制。在附图中:The accompanying drawings are used to provide a further understanding of the present invention, and constitute a part of the description, together with the following specific embodiments, are used to explain the present invention, but do not constitute a limitation to the present invention. In the attached picture:

图1为实施例1所合成的泊沙康唑的核磁氢谱图;Fig. 1 is the proton nuclear magnetic spectrum figure of the posaconazole synthesized in embodiment 1;

图2为实施例1所合成的泊沙康唑的核磁碳谱图。Figure 2 is the carbon NMR spectrum of posaconazole synthesized in Example 1.

具体实施方式detailed description

在实施例1至4中所采用的式II所示结构的化合物的合成方法如下:The synthetic method of the compound of the structure shown in the formula II adopted in embodiment 1 to 4 is as follows:

在100ml三口瓶中加入2-[(1S,2S)-1-乙基-2-苄氧基丙基]-2,4-二氢-4-[4-[4-(4-羟基苯基)-1-哌嗪基]苯基]-3H-1,2,4-三氮唑-3-酮(4.78g)和DMSO(40ml),搅拌溶解,加入浓度25wt%的NaOH水溶液(1.6ml),混合搅拌10分钟,加入(5R-CIS)-甲苯-4-磺酸5-(2,4-二氟苯基)-5-(1H-1,2,4-三氮唑-1-基)甲基四氢呋喃-3-基甲基酯(4.4g),混合物30℃反应约14h,液相监测至反应完毕,将反应液倒入剧烈搅拌的水(240ml)中,加毕,再剧烈搅拌10min,过滤,滤饼用水洗涤,将滤饼用异丙醇重结晶后得到固体,真空干燥得到灰白色粉末固体(式II);经核磁、质谱以及红外光谱综合检测可知,该灰色粉末固体为式II所述化合物,且该化合物的纯度为>99%。Add 2-[(1S,2S)-1-ethyl-2-benzyloxypropyl]-2,4-dihydro-4-[4-[4-(4-hydroxyphenyl )-1-piperazinyl]phenyl]-3H-1,2,4-triazol-3-one (4.78g) and DMSO (40ml), stirring and dissolving, adding NaOH aqueous solution (1.6ml ), mixed and stirred for 10 minutes, added (5R-CIS)-toluene-4-sulfonic acid 5-(2,4-difluorophenyl)-5-(1H-1,2,4-triazole-1- base) methyltetrahydrofuran-3-ylmethyl ester (4.4g), the mixture was reacted at 30°C for about 14h, the liquid phase was monitored until the reaction was complete, the reaction solution was poured into vigorously stirred water (240ml), the addition was completed, and then vigorously Stir for 10min, filter, wash the filter cake with water, obtain a solid after the filter cake is recrystallized with isopropanol, and vacuum dry to obtain an off-white powder solid (formula II); through nuclear magnetic, mass spectrometry and infrared spectrum comprehensive detection, it can be known that this gray powder solid is The compound described in formula II, and the purity of the compound is >99%.

实施例1Example 1

用于说明本发明泊沙康唑及其的合成方法For illustrating the present invention posaconazole and its synthetic method

(1)内置有搅拌器的反应釜结构:(1) Reactor structure with built-in agitator:

该反应釜的高度为120cm,直径为50cm的100L搪瓷反应釜。其中设有搅拌器和一组挡板组,所述搅拌器为标配,包括沿所述反应釜的轴线方向设置的搅拌轴和沿所述搅拌轴的轴线方向均布的两组组搅拌叶片组,各组搅拌叶片组平行设置,且每组搅拌叶片组中包括两片沿所述搅拌轴周向均布的搅拌叶片,每片搅拌叶片沿所述反应釜径向方向的长度8cm;所述挡板组包括高度为60cm,宽度为5cm,厚度为1cm的4个挡板,各挡板的长度方向沿平行于所述搅拌器的轴线方向设置(一侧固定在所述反应釜的底壁上)、宽度方向沿所述反应釜的径向方向设置,各挡板沿其宽度延伸的方向(一侧固定在所述反应釜的侧壁上,另一侧朝向所述搅拌器的位置延伸),且各挡板以所述搅拌器的轴线为垂直中分线呈圆周分布。The reactor has a height of 120cm and a diameter of 100L enamel reactor of 50cm. There is a stirrer and a set of baffle plates, the stirrer is standard, including a stirring shaft arranged along the axis of the reactor and two sets of stirring blades uniformly distributed along the axis of the stirring shaft Groups, each group of stirring blade groups are arranged in parallel, and each group of stirring blade groups includes two stirring blades uniformly distributed along the circumference of the stirring shaft, and the length of each stirring blade along the radial direction of the reactor is 8cm; The plate group includes a height of 60 cm, a width of 5 cm, and a thickness of 4 baffles of 1 cm. The length direction of each baffle is arranged along the axial direction parallel to the stirrer (one side is fixed on the bottom wall of the reactor. ), the width direction is arranged along the radial direction of the reactor, and each baffle is extended along the direction of its width (one side is fixed on the side wall of the reactor, and the other side extends towards the position of the agitator) , and the baffles are circumferentially distributed with the axis of the agitator as the vertical midline.

(2)泊沙康唑的合成(2) Synthesis of posaconazole

在上述100L搪瓷反应釜中加入60L甲醇,4kg式II所示化合物,4L浓度为36.5wt%的盐酸,320g的10%钯碳催化剂(含水50%),密封反应釜,开启搅拌器(搅拌速度为350rpm)。先用氮气置换釜内空气3次,再用氢气置换3次,氢气压力保持在0.1MPa(表压),升温加热至50℃,HPLC监测反应,2h反应结束。降温,用氮气置换3次,过滤得到10%钯碳催化剂。将滤液倒入另一个200L搪瓷反应釜中,加入冰块,降温至0-5℃,向滤液中滴加2mol/LNaOH溶液,调节pH至11,有大量固体析出,搅拌2h后,离心,并用水洗涤滤饼3次,将固体放于55℃鼓风干燥箱中干燥,得到3.32kg的产物,附图1示出了该产物的核磁氢谱图,附图2示出了该产物的核磁碳谱图,结合附图1和2可知,该产物正是所需泊沙康唑,经计算该产物的收率为93.6%,HPLC纯度为99.754%。Add 60L methyl alcohol in above-mentioned 100L enamel reactor, compound shown in 4kg formula II, 4L concentration is the hydrochloric acid of 36.5wt%, the 10% palladium carbon catalyst (water content 50%) of 320g, seal reactor, open agitator (stirring speed is 350rpm). First replace the air in the kettle with nitrogen for 3 times, and then replace it with hydrogen for 3 times. The hydrogen pressure is kept at 0.1 MPa (gauge pressure), and the temperature is raised to 50 ° C. The reaction is monitored by HPLC, and the reaction is completed after 2 hours. Cool down, replace with nitrogen for 3 times, and filter to obtain 10% palladium carbon catalyst. Pour the filtrate into another 200L enamel reaction kettle, add ice cubes, cool down to 0-5°C, add 2mol/L NaOH solution dropwise to the filtrate, adjust the pH to 11, a large amount of solids precipitate, stir for 2 hours, centrifuge, and The filter cake was washed with water for 3 times, and the solid was dried in a blast drying oven at 55° C. to obtain a product of 3.32 kg. Accompanying drawing 1 shows the H NMR spectrum of the product, and Accompanying drawing 2 shows the NMR of the product. The carbon spectrogram, combined with accompanying drawings 1 and 2, shows that the product is exactly the desired posaconazole, and the calculated yield of the product is 93.6%, and the HPLC purity is 99.754%.

实施例2Example 2

用于说明本发明泊沙康唑及其的合成方法For illustrating the present invention posaconazole and its synthetic method

(1)内置有搅拌器的反应釜结构:同实施例1。(1) Built-in reactor structure of agitator: same as embodiment 1.

(2)泊沙康唑的合成:(2) Synthesis of posaconazole:

在前述100L的搪瓷反应釜中加入,加入60L甲醇,4kg式II所示化合物,6L浓度为98wt%的硫酸,400g的10%钯碳催化剂(含水50%),密封反应釜,开启搅拌器(搅拌速度为400rpm)。先用氮气置换釜内空气3次,再用氢气置换3次,氢气压力保持在0.1MPa(表压),升温加热至55℃,HPLC监测反应,2h反应结束。降温,用氮气置换3次,过滤得到10%钯碳催化剂。将滤液倒入另一个200L搪瓷反应釜中,加入冰块,降温至0-5℃,向滤液中滴加2mol/LNaOH溶液,调节pH至12,有大量固体析出,搅拌2h后,离心,并用水洗涤滤饼3次,将固体放于55℃鼓风干燥箱中干燥,得到3.27kg的产物,通过核磁氢谱图核磁碳谱图可知,该产物正是所需泊沙康唑,经计算该产物的收率为92.3%,HPLC纯度为99.594wt%。Add in the enamel reactor of aforementioned 100L, add 60L methyl alcohol, compound shown in 4kg formula II, 6L concentration is the sulfuric acid of 98wt%, 10% palladium carbon catalyst (water content 50%) of 400g, seal reactor, open stirrer ( Stirring speed is 400rpm). First replace the air in the kettle with nitrogen for 3 times, then replace it with hydrogen for 3 times, keep the pressure of hydrogen at 0.1 MPa (gauge pressure), raise the temperature to 55°C, monitor the reaction by HPLC, and the reaction is completed after 2 hours. Cool down, replace with nitrogen for 3 times, and filter to obtain 10% palladium carbon catalyst. Pour the filtrate into another 200L enamel reaction kettle, add ice cubes, cool down to 0-5°C, add 2mol/L NaOH solution dropwise to the filtrate, adjust the pH to 12, a large amount of solids precipitate, stir for 2 hours, centrifuge, and The filter cake was washed with water for 3 times, and the solid was dried in a blast drying oven at 55°C to obtain 3.27 kg of the product. According to the H NMR spectrum and the C NMR spectrum, the product was exactly the desired posaconazole. After calculation The yield of the product was 92.3%, and the HPLC purity was 99.594 wt%.

实施例3Example 3

用于说明本发明泊沙康唑及其的合成方法For illustrating the present invention posaconazole and its synthetic method

(1)内置有搅拌器的反应釜结构:同实施例1;(1) built-in reactor structure with stirrer: same as embodiment 1;

(2)泊沙康唑的合成:(2) Synthesis of posaconazole:

在前述100L的搪瓷反应釜中加入,加入60L甲醇,4kg式II所示化合物,4L浓度为36.5wt%的盐酸,200g的10%钯碳催化剂(含水50%),密封反应釜,开启搅拌器(搅拌速度为450rpm)。先用氮气置换釜内空气3次,再用氢气置换3次,氢气压力保持在0.12MPa,升温加热至50℃,HPLC监测反应,3h反应结束。降温,用氮气置换3次,过滤得到10%钯碳催化剂(备用)。将滤液倒入另一个200L搪瓷反应釜中,加入冰块,降温至0-5℃,向滤液中滴加2mol/L Na2CO3溶液,调节pH至10,有大量固体析出,搅拌2h后,离心,并用水洗涤滤饼3次,将固体放于55℃鼓风干燥箱中干燥,得到3.24kg的产物,通过核磁氢谱图核磁碳谱图可知,该产物正是所需泊沙康唑,经计算该产物的收率为91.4%,HPLC纯度为99.125%。Add in the enamel reactor of aforementioned 100L, add 60L methyl alcohol, the compound shown in 4kg formula II, 4L concentration is the hydrochloric acid of 36.5wt%, the 10% palladium carbon catalyst (water content 50%) of 200g, seal reactor, open stirrer (Stirring speed is 450rpm). First replace the air in the kettle with nitrogen for 3 times, then replace it with hydrogen for 3 times, keep the pressure of hydrogen at 0.12MPa, raise the temperature to 50°C, monitor the reaction by HPLC, and the reaction is completed in 3 hours. Cool down, replace with nitrogen for 3 times, and filter to obtain 10% palladium-carbon catalyst (standby). Pour the filtrate into another 200L enamel reaction kettle, add ice cubes, cool down to 0-5°C, add 2mol/L Na 2 CO 3 solution dropwise to the filtrate, adjust the pH to 10, a large amount of solids precipitate out, stir for 2 hours , centrifuged, and washed the filter cake with water for 3 times, and dried the solid in a blast oven at 55°C to obtain 3.24kg of the product. According to the H NMR spectrum and the NMR C spectrum, the product is exactly the desired posacon azole, the yield of the product was calculated to be 91.4%, and the HPLC purity was 99.125%.

实施例4Example 4

用于说明本发明泊沙康唑及其的合成方法For illustrating the present invention posaconazole and its synthetic method

(1)内置有搅拌器的反应釜结构:该反应釜的高度为120cm,直径为50cm的100L搪瓷反应釜。其中设有搅拌器(未设挡板),所述搅拌器包括沿所述反应釜的轴线方向设置的搅拌轴和沿所述搅拌轴的轴线方向均布的四组搅拌叶片组,各组搅拌叶片组平行设置,且每组搅拌叶片组中包括3片沿所述搅拌轴周向均布的搅拌叶片,搅拌叶片沿所述反应釜径向方向的长度8cm。(1) Reactor structure with a built-in stirrer: the height of the reactor is 120cm, and the diameter is 100L enamel reactor of 50cm. Wherein a stirrer (no baffle plate) is provided, and the stirrer includes a stirring shaft arranged along the axial direction of the reaction kettle and four groups of stirring blade groups uniformly distributed along the axial direction of the stirring shaft, each group of stirring The blade groups are arranged in parallel, and each group of stirring blade groups includes 3 stirring blades uniformly distributed along the circumference of the stirring shaft, and the length of the stirring blades along the radial direction of the reactor is 8 cm.

(2)泊沙康唑的合成:参照实施例中泊沙康唑的合成,经反应得到3.19kg的产物,通过核磁氢谱图核磁碳谱图可知,该产物正是所需泊沙康唑,经计算该产物的收率为90.1%,HPLC纯度为98.565%。(2) Synthesis of posaconazole: with reference to the synthesis of posaconazole in the examples, the product of 3.19kg is obtained through reaction, as can be known by the proton nuclear magnetic spectrum and the carbon nuclear magnetic spectrum, this product is exactly required posaconazole, The calculated yield of the product was 90.1%, and the HPLC purity was 98.565%.

从上述实施例的结果中能够看出,利用本发明的方法合成式(I)的化合物简便易行,而且反应效率高且产率高。而且,如上文所述,US5625064和CN101824009A中报道技术方法需要反应40h;WO2013042138A2和US2014343285A1中报道技术虽反应时间为5h,但目标产物经过异丙醇重结晶后纯度才达到99.85%;CN102863431A中报道技术方法的后处理太繁琐,且纯度太低(93.9%)。本发明通过以氢气为氢源,在搅拌条件(设置搅拌器和任选的挡板)下完成氢化脱苄基反应,明显缩短了反应时间(2-3h),且后处理简便,纯度高(>98.5%)。本发明的方法克服了现有技术的托法替布合成方法中的合成工艺过程复杂,生产周期长的缺陷,适合于大规模工业化生产。而且,在合成泊沙康唑的后续处理工艺中,利用本发明所述方法合成能够减少杂质的引入,有利于在药学领域的应用。From the results of the above examples, it can be seen that the synthesis of the compound of formula (I) by the method of the present invention is simple and easy, and the reaction efficiency is high and the yield is high. Moreover, as mentioned above, the technical method reported in US5625064 and CN101824009A needs to react for 40 hours; although the reaction time of the technology reported in WO2013042138A2 and US2014343285A1 is 5 hours, the purity of the target product reaches 99.85% after recrystallization from isopropanol; the technology reported in CN102863431A The post-processing of the method is too cumbersome, and the purity is too low (93.9%). The present invention completes the hydrogenation debenzylation reaction by using hydrogen as the hydrogen source under stirring conditions (stirrer and optional baffle are set), which obviously shortens the reaction time (2-3h), and the aftertreatment is simple and easy, and the purity is high ( >98.5%). The method of the invention overcomes the defects of complex synthesis process and long production cycle in the synthesis method of tofacitinib in the prior art, and is suitable for large-scale industrial production. Moreover, in the subsequent treatment process of synthesizing posaconazole, using the synthesis method of the present invention can reduce the introduction of impurities, which is beneficial to the application in the field of pharmacy.

以上所述仅为本发明的优选实施例而已,并不用于限制本发明,对于本领域的技术人员来说,本发明可以有各种更改和变化。凡在本发明的精神和原则之内,所作的任何修改、等同替换、改进等,均应包含在本发明的保护范围之内。The above descriptions are only preferred embodiments of the present invention, and are not intended to limit the present invention. For those skilled in the art, the present invention may have various modifications and changes. Any modifications, equivalent replacements, improvements, etc. made within the spirit and principles of the present invention shall be included within the protection scope of the present invention.

Claims (10)

1. a kind of synthetic method of posaconazole is it is characterised in that the synthetic method of described posaconazole comprises the following steps:
S1, with compound as shown in following formula ii as raw material, with hydrogen as hydrogen source, hydrogenation debenzylation under the conditions of, will be described Compound shown in formula ii stirs haptoreaction with catalyst and acid reagent in reaction dissolvent, obtains mixed solution;
S2, described mixed solution is cooled to 0-5 DEG C, to described mixed solution and dripping sodium hydroxide solution to mixed solution Ph value is 10-12, and agitation and filtration obtains filter cake, is dried to obtain the posaconazole as shown in following formula i after cleaning,
2. method according to claim 1 it is characterised in that in described step s1 catalyst be water content be 50wt% 10wt% palladium-carbon catalyst, and water content be 50wt% 10wt% palladium-carbon catalyst with the weight ratio of compound shown in formula ii be (0.05-0.1): 1, preferably (0.08-1): 1, more preferably 0.08:1.
3. method according to claim 1 it is characterised in that acid reagent described in described step s1 be mineral acid and/ Or organic acid, preferably described acid reagent is (0.5-1.5) l:1kg with the envelope-bulk to weight ratio of compound shown in formula ii, more preferably For 1l:1kg.
4. method according to claim 1 includes it is characterised in that hydrogenating debenzylation condition in described step s1: Under conditions of normal pressure, temperature are 50-55 DEG C, with the speed of 350-450rpm, stirring reaction 2-3h.
5. method according to claim 1 is it is characterised in that described step s1 is entered in the reactor be built-in with agitator OK.
6. method according to claim 5 it is characterised in that in described reactor agitator include shaft and along described The uniform multigroup stirring vane group of the axis direction of shaft, is included in each stirring vane group respectively along described shaft circumference 1 to 3 uniform stirring vane.
7. the method according to claim 5 or 6 is it is characterised in that be additionally provided with least one set baffle group in described reactor, Described one group of baffle group includes the length direction of multiple baffle plates and each described baffle plate along the axis side parallel to described agitator Arrange to setting, width along the radial direction of described reactor;
Preferably described agitator is along the axis setting of described reactor, and in described one group of baffle group, each described baffle plate is stirred with described The axis mixing device is that vertically middle separated time is circumferentially distributed.
8. method according to claim 7 it is characterised in that
It is provided with one group of baffle group, and the direction that in this baffle group, each baffle plate extends along its width, side is fixed in described reactor On the inwall of described reactor, opposite side extends towards the position of described agitator;Or
Two groups or three groups of baffle group are set in described reactor, and each described baffle group is with the axis of described agitator in vertical point Line is in that the baffle plate in concentric circular setting and two adjacent groups baffle group is crisscross arranged.
9. method according to claim 1 it is characterised in that described acid reagent be hydrochloric acid, sulphuric acid, glacial acetic acid, formic acid One or more of with benzenesulfonic acid, preferably described acid reagent is hydrochloric acid.
10. the posaconazole that in a kind of claim 1 to 9, the method synthesis described in any one obtains, preferably described pool sand health Purity >=99% of azoles.
CN201610755734.XA 2016-08-29 2016-08-29 A kind of synthetic method of posaconazole Active CN106366076B (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201610755734.XA CN106366076B (en) 2016-08-29 2016-08-29 A kind of synthetic method of posaconazole

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201610755734.XA CN106366076B (en) 2016-08-29 2016-08-29 A kind of synthetic method of posaconazole

Publications (2)

Publication Number Publication Date
CN106366076A true CN106366076A (en) 2017-02-01
CN106366076B CN106366076B (en) 2019-07-16

Family

ID=57901841

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201610755734.XA Active CN106366076B (en) 2016-08-29 2016-08-29 A kind of synthetic method of posaconazole

Country Status (1)

Country Link
CN (1) CN106366076B (en)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106883221A (en) * 2017-04-17 2017-06-23 兰州大学 A kind of amorphous posaconazole and preparation method thereof
CN109970725A (en) * 2019-03-29 2019-07-05 武汉朗来科技发展有限公司 The preparation method of posaconazole
CN112824400A (en) * 2019-11-20 2021-05-21 华创合成制药股份有限公司 Preparation method of posaconazole
CN116041338A (en) * 2022-11-11 2023-05-02 苏州汉德创宏生化科技有限公司 Preparation method of posaconazole
WO2023122868A1 (en) * 2021-12-27 2023-07-06 浙江海正药业股份有限公司 Posaconazole impurity reference substance and preparation method therefor

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013042138A2 (en) * 2011-09-19 2013-03-28 Msn Laboratories Limited Process for the preparation of triazole antifungal drug, its intermediates and polymorphs thereof
CN104761555A (en) * 2015-03-21 2015-07-08 河北国龙制药有限公司 Tofacitinib intermediate preparation method and method for preparing tofacitinib or its salt by using tofacitinib intermediate preparation method

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013042138A2 (en) * 2011-09-19 2013-03-28 Msn Laboratories Limited Process for the preparation of triazole antifungal drug, its intermediates and polymorphs thereof
CN104761555A (en) * 2015-03-21 2015-07-08 河北国龙制药有限公司 Tofacitinib intermediate preparation method and method for preparing tofacitinib or its salt by using tofacitinib intermediate preparation method

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
张秋荣等: "《制药工艺学》", 31 August 2007 *
陈乙崇: "《搅拌设备设计》", 30 November 1985 *

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106883221A (en) * 2017-04-17 2017-06-23 兰州大学 A kind of amorphous posaconazole and preparation method thereof
CN109970725A (en) * 2019-03-29 2019-07-05 武汉朗来科技发展有限公司 The preparation method of posaconazole
CN112824400A (en) * 2019-11-20 2021-05-21 华创合成制药股份有限公司 Preparation method of posaconazole
WO2023122868A1 (en) * 2021-12-27 2023-07-06 浙江海正药业股份有限公司 Posaconazole impurity reference substance and preparation method therefor
CN116041338A (en) * 2022-11-11 2023-05-02 苏州汉德创宏生化科技有限公司 Preparation method of posaconazole

Also Published As

Publication number Publication date
CN106366076B (en) 2019-07-16

Similar Documents

Publication Publication Date Title
CN106366076A (en) Posaconazole synthesis method
CN103570580B (en) Preparation method of high-purity iopromide
CN107915738B (en) For synthesizing Ba Rui for the preparation method of the key intermediate 2 of Buddhist nun
CN104292214A (en) Synthesis method of efinaconazole and intermediate thereof
CN106256824A (en) A kind of preparation method of high-purity De Lasha star meglumine salt
CN105085544B (en) A kind of synthetic method of Tazobactam Sodium benzhydryl ester
WO2013020460A1 (en) Atazanavir preparation method
CN107235957A (en) A kind of synthetic method for preparing Niraparib
CN107235959A (en) A kind of novel method for synthesizing for preparing cancer therapy drug Niraparib
CN107235967B (en) Synthetic Technology of Antineoplastic Drug Tegafur
CN108239077A (en) A kind of novel preparation method of posaconazole and its intermediate
CN111087324B (en) Synthesis method of doramexane
CN108358900A (en) A kind of preparation method of Afatinib and its maleate
EP2643306B1 (en) Process for the preparation of deferasirox
JP7630444B2 (en) Process for preparing XPO1 inhibitors and intermediates used in the preparation of XPO1 inhibitors
WO2012164242A1 (en) Process for the preparation of paliperidone
CN104703967B (en) The process for purification of fluvoxamine free alkali and the preparation method of the high-purity fluvoxamine maleate using which
WO2024037212A1 (en) Preparation method for isavuconazonium sulfate
CN107954936A (en) A kind of method for preparing deuterated Imidazole diketone compound
CN102250083B (en) Method for preparing ziprasidone
CN105272921A (en) Method for preparing Ceritinib and intermediate compound of Ceritinib
CN103508898A (en) Novel preparation method of alverine citrate
CN101613317B (en) Mozavaptan synthesis technology for treating congestive heart failure (CHF)
CN111116493A (en) A kind of method for preparing Apabetalone, intermediate and preparation method thereof
CN116924886A (en) Synthesis method of 8-oxo-2,2,14,14-tetramethylpentadecanedioic acid

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant
TR01 Transfer of patent right
TR01 Transfer of patent right

Effective date of registration: 20200603

Address after: 061100 West Zone and east side of Jingliu Road, Lingang Economic and Technological Development Zone, Cangzhou City, Hebei Province

Patentee after: HEBEI GUANGXIANG PHARMACEUTICAL Co.,Ltd.

Address before: 052165, Hebei, Shijiazhuang Shijiazhuang economic and Technological Development Zone, Yang Zi Road, Societe Generale Road West

Patentee before: HEBEI GUOLONG PHARMACEUTICAL Co.,Ltd.